Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback